Can a Discontinued Device Still Be a 510(k) Predicate?

The short answer: discontinued does not mean disqualified

Consider a common regulatory scenario: your engineering team has identified a comparator device whose clinical indications, mechanism of action, and technological parameters match your subject device almost perfectly. The device received 510(k) clearance eight years ago, enjoyed several years of unremarkable clinical use, and was quietly withdrawn from commercial distribution two years ago due to a corporate portfolio consolidation. There were no safety alerts, no mandatory field actions, and no regulatory sanctions. Can you still name this retired device as your primary predicate in a new 510(k) premarket notification? How do you demonstrate substantial equivalence when you cannot purchase a unit for head-to-head laboratory testing? And under what circumstances should you abandon the discontinued comparator in favor of a currently marketed device?

The definitive answer from FDA is yes. In its published guidance on how to find and effectively use predicate devices, the CDRH states plainly: “An applicant may claim SE to a device that is no longer being marketed in the U.S.” In U.S. medical device law, predicate eligibility is governed by legal classification and marketing authorization, not commercial inventory. When a manufacturer ceases production, dissolves a product line, or surrenders market share, the underlying 510(k) clearance does not expire, dissolve, or revert to an unapproved state.

Commercial availability is an operational reality; legal marketing status is a regulatory attribute. As long as the comparator met the criteria for a legally marketed device and has not been stripped of that status through formal government enforcement, it remains an eligible benchmark for substantial equivalence under section 513(i) of the FD&C Act. What changes when a predicate is discontinued is not the statutory rule of eligibility, but the practical burden of proof. When bench comparison units cannot be bought off the shelf, regulatory affairs teams must establish equivalence through public technical records, consensus standards compliance, and rigorous predicate provenance tracking.

What 'legally marketed' actually requires

To understand why a discontinued device remains eligible, one must examine how the law defines a predicate. Under 21 CFR 807.92(a)(3), an applicant filing a 510(k) summary must identify the legally marketed device to which equivalence is claimed. Across FDA regulations, guidance documents, and administrative precedents, a legally marketed device falls into one of four recognized categories:

• Preamendment Devices: A device that was legally in commercial distribution in the United States prior to May 28, 1976 (the enactment date of the Medical Device Amendments), and has not been significantly changed in design or intended use since that date.

• 510(k)-Cleared Devices: A device originally cleared by FDA through the premarket notification pathway under 21 CFR Part 807, Subpart E, having received an official Substantial Equivalence determination order.

• Downclassified Devices: A device initially categorized in Class III that was subsequently reclassified into Class II or Class I through an FDA administrative order or rulemaking proceeding.

• 510(k)-Exempt Commercial Devices: A Class I or Class II device that is exempt by regulation from premarket notification requirements under 21 CFR Parts 862–892 and is legally marketed in commercial distribution.

In addition to belonging to one of these four categories, a predicate device carries a single non-negotiable negative constraint: it cannot be a device that is or was in violation of the FD&C Act. This foundational rule excludes devices that were introduced to interstate commerce without required premarket clearance, marketed under unapproved indications, or adulterated during manufacturing.

When dealing with a discontinued preamendment device, the evidentiary threshold is notably demanding. Because preamendment devices predate the 510(k) numbering architecture, they have no K-number in CDRH databases. A submitter citing a discontinued preamendment predicate must compile historical invoices, archival catalog cut sheets, promotional brochures, and dated packaging specimens proving that the device was actively marketed in interstate commerce prior to May 28, 1976, and that its intended use has remained unchanged. For modern device development, citing a discontinued 510(k)-cleared postamendment device is significantly more straightforward, as its clearance record is permanently captured in CDRH public archives. Submitters evaluating pathway options should review our foundational overview on 510(k) predicate devices and selection strategy as well as our analysis of 510(k)-exempt product codes and surviving compliance duties.

The configuration-to-claim-to-evidence map

The single greatest source of regulatory confusion surrounding retired medical devices is the failure to distinguish between manufacturer-driven business decisions and government-enforced legal disqualifications. Under section 513(i)(2) of the FD&C Act (21 U.S.C. 360c(i)(2)) and 21 CFR 807.100(b)(3), Section 513(i)(2) bars a substantial-equivalence finding when the cited predicate device:

1. Has been removed from the market at the initiative of the Secretary (delegated to the Commissioner of Food and Drugs); or

2. Has been determined to be misbranded or adulterated by a judicial order.

Every other permutation of market withdrawal—ranging from strategic commercial obsolescence to voluntary safety recalls—leaves the underlying regulatory clearance intact. The table below maps each device status configuration to its statutory classification, allowable regulatory claims, and required filing evidence.

As the map demonstrates, statutory disqualification is extremely narrow. An administrative Warning Letter, a 483 inspectional observation, or a voluntary recall under 21 CFR Part 7 does not constitute a removal at the initiative of the Secretary. FDA's 2023 draft guidance states that recalls are typically voluntary manufacturer actions. Reporting a correction or removal under 21 CFR Part 806 is a separate duty and does not itself mean FDA removed the device. A mandatory recall order under section 518(e) of the FD&C Act (21 U.S.C. 360h(e)) is one example of removal at FDA's initiative. The statute does not define the exact point at which an FDA request becomes removal at the Secretary's initiative, so a borderline file belongs in a Q-Submission rather than a self-declared eligibility opinion.

Required evidence, voluntary best practices, and commercial assumptions

When developing a 510(k) strategy around a retired comparator, regulatory professionals frequently conflate three distinct categories of rules: mandatory statutory and regulatory requirements, nonbinding agency recommendations, and informal commercial assumptions. Disentangling these three layers is essential to building an unassailable submission file.

Under Layer 1 (Binding Regulation), the statutory standard under section 513(i)(1)(A) requires that the subject device have the same intended use as the predicate, and either have the same technological characteristics, or have different technological characteristics that do not raise different questions of safety and effectiveness. Under 21 CFR 807.87(f), the 510(k) must include “a statement indicating the device is similar to and/or different from other products of comparable type in commercial distribution, accompanied by data to support the statement.” Under 21 CFR 807.92, the public 510(k) summary must clearly identify the predicate device and provide an explicit technological comparison. None of these regulations require that the comparator be actively produced on the date of submission.

Under Layer 2 (FDA Best Practices), submitters must navigate FDA's modern regulatory expectations. In September 2023, FDA issued a high-profile draft guidance entitled “Best Practices for Selecting a Predicate Device to Support a Premarket Notification [510(k)] Submission” (Docket FDA-2023-D-3134). As of September 2026, this document remains in draft, nonbinding status. It outlines four qualitative best practices for predicate selection:

1. The predicate device was cleared using well-established test methods (e.g., recognized consensus standards or FDA guidance documents).

2. The predicate device meets or exceeds expected safety and performance criteria.

3. The predicate device has no unmitigated use-related or design-related safety issues (identified via postmarket databases).

4. The predicate device does not have an associated design-related recall.

Industry commentators often mischaracterize these four points as rigid disqualification gates. They are not. In the draft guidance itself, FDA explicitly acknowledges that an ideal best-practice predicate may not always exist. When an applicant must cite a predicate that falls short of these criteria—such as a discontinued device with an older testing pedigree or a resolved field action—FDA advises the applicant to include an explicit mitigation narrative in the Performance Data section of the 510(k) Summary. The applicant must explain how the subject device's design, verification protocols, and risk management prevent the historical shortcomings of the predicate from recurring. For an in-depth exploration of postmarket screening workflows, see our dedicated analysis on FDA 510(k) predicate selection best practices, recall history, and the QMSR gate.

Furthermore, FDA's history regarding predicate age is instructive. In early 2019, CDRH published a public docket exploring whether the agency should aggressively discourage or restrict the use of predicates older than ten years. Following vigorous public feedback from manufacturers, standards bodies, and clinicians, FDA declined to restrict predicates solely because they were more than ten years old. Stakeholders demonstrated that in mature device sectors (such as metallic orthopedic fixation, manual surgical instruments, and catheter tubing), decades of stable clinical use provide an invaluable benchmark of real-world safety, whereas newer devices often lack long-term biocompatibility and wear data. In fact, in the 2023 draft guidance's own illustrative case study for an intervertebral fusion device, FDA selected a 15-year-old predicate over a 3-year-old alternative specifically because the older device possessed an established, well-documented clinical safety profile. Age and discontinuation alone do not impair predicate utility.

Finally, consider Layer 3 (Commercial Assumptions). In the FDA Unique Device Identification (UDI) ecosystem, the Global UDI Database (GUDID) tracks commercial distribution. When a labeler discontinues a device, it updates the record with a Commercial Distribution End Date, which the system uses to show “Not In Commercial Distribution” in AccessGUDID. FDA's GUDID guidance states that published device-identifier records for devices removed from commercial distribution remain publicly retrievable. Commercial Distribution Status is labeler-declared commercial data. It is not a predicate-eligibility finding, and the absence of an end date is not proof that the device is still distributed. For a comparison of database roles, read our guide on AccessGUDID versus FDA device registration and listing.

Documenting a device you cannot buy: the evidentiary workflow

When a predicate device is actively marketed, verifying its performance is straightforward: regulatory engineers purchase commercial units, subject them to side-by-side dimensional inspections, material analyses, and bench testing, and file comparative data. When the predicate is discontinued, physical procurement is often impossible. Regulatory teams must pivot to an evidentiary workflow based on archival public records and standardized performance benchmarks.

flowchart TD
    A["Identify Candidate Predicate"] --> B{"Check Releasable 510(k) File"}
    B -->|"WD, NE, RE, or DE"| C["Not a usable clearance record"]
    B -->|"Completed SE decision"| D{"Check Removal Status"}
    D -->|"Removed at Secretary's Initiative"| E["Barred as a predicate by section 513(i)(2)"]
    D -->|"Judicial Misbranding or Adulteration"| F["Barred as a predicate by section 513(i)(2)"]
    D -->|"Voluntary Discontinuation"| G{"Inspect SUMMARY vs STATEMENT"}
    G -->|"STATEMENT and manufacturer unreachable"| H["Public safety and effectiveness data may be unavailable"]
    G -->|"SUMMARY available"| I["Extract IFU, characteristics, and standards"]
    I --> J{"Postmarket Safety Screen"}
    J -->|"Design-related recall or open safety signal"| K["Legally usable: mitigation narrative and performance data"]
    J -->|"No design-related recall signal"| L["Eligible discontinued predicate: build the comparison file"]
    C --> M["Select another predicate or consider De Novo"]
    E --> M
    F --> M
    H --> M

Step 1: Database verification and decision code audit

Before investing resources in drafting equivalence tables, examine the raw database record in the FDA Releasable 510(k) file layout. A search in the public web portal is necessary, but downloading the underlying CDRH dataset reveals critical administrative codes:

• Substantial Equivalence Decision Codes (read the description): A completed substantial-equivalence decision is usually coded SE. FDA's releasable file also lists administrative SE-family codes whose descriptions are not interchangeable with a completed clearance. Examples include KD (Substantially Equivalent — Kit with Drugs), SA (Substantially Equivalent — Awaiting Device Approval), SF (Substantially Equivalent — Awaiting Future Policies), SK (Substantially Equivalent — Kit). Read the decision description before treating any of those codes as an unrestricted clearance you can cite.

• Disqualifying Decision Codes (Ineligible): Confirm the absence of WD (Withdrawn by Applicant), NE (Not Substantially Equivalent), RE (Rescind Substantial Equivalence), and DE (Deleted from file). If a candidate comparator carries a WD or NE decision code, it never conferred legal marketing authorization, regardless of whether prototypes were displayed or distributed. If it carries an RE code, its clearance was formally annulled.

For detailed database interrogation techniques, consult our comprehensive handbook on searching the FDA 510(k) database for predicate intelligence and our decoder for FDA 510(k) K-numbers and regulatory tracking.

Step 2: The 510(k) Summary versus Statement trap

The greatest administrative trap in using a discontinued predicate lies in the historic SUMMARY/STATEMENT field of the 510(k) clearance database. Under the Safe Medical Devices Act of 1990 and 21 CFR 807.87(h), a premarket notification submitter had two statutory options for addressing safety and effectiveness data:

1. 510(k) Summary (21 CFR 807.92): The applicant submitted a public document outlining the device's technological characteristics, intended use, and performance testing summaries. When this option was selected, FDA scanned and archived the document, making it permanently downloadable from the CDRH database.

2. 510(k) Statement (21 CFR 807.93): The applicant filed a formal certification promising that it would make safety and effectiveness data available to any interested person within 30 days of receiving a written request. FDA did not require or publish a substantive summary in the public database.

If your candidate discontinued predicate was cleared under a 510(k) Statement, and the original manufacturer has subsequently ceased operations, filed for bankruptcy, or merged into an unresponsive corporate entity, the safety and effectiveness information may be unavailable from the applicant. You cannot compel a dissolved company to answer a 21 CFR 807.93 request within 30 days. Freedom of Information Act (FOIA) requests to FDA for historical review memoranda often take months or years—exceeding reasonable submission timelines. Therefore, verify immediately that the candidate predicate has an accessible, public 510(k) Summary.

Step 3: Reconstructing technical specifications without physical samples

When physical comparator units cannot be tested side-by-side in your laboratory, how do you satisfy the comparative data requirements of 21 CFR 807.87(f)? The answer lies in objective standard benchmarking FDA does not publish a rule that compliance with a recognized consensus standard automatically replaces a technological comparison. When the predicate's 510(k) Summary identifies the methods and performance window, testing the subject device to the current recognized version of those standards can supply part of the supporting data under 21 CFR 807.87(f):

• FDA Recognized Consensus Standards: Identify the standards declared in the predicate's 510(k) Summary (e.g., ISO 10993-1 for biocompatibility, IEC 60601-1 for electrical safety, or ASTM F2077 for spinal implants). By testing your subject device against the current recognized versions of these consensus standards, you provide objective, reproducible proof of safety and performance without needing physical comparator units.

• Public Technical Documentation: Extract exact dimensional envelopes, materials, energy deliveries, and user interfaces from the predicate's public Indications for Use (IFU) statement, operator manuals, commercial catalogs archived by web repositories, and peer-reviewed clinical literature.

• FOIA Redacted Review Memoranda: For critical older clearances where public summaries are sparse, submit an expedited FOIA request or review existing FOIA electronic reading room releases. FDA's internal review memo frequently details the exact mechanical thresholds, animal study endpoints, and acceptance criteria required for the original clearance.

Step 4: Postmarket safety and recall surveillance

Before finalizing a discontinued predicate, conduct exhaustive surveillance across FDA's postmarket surveillance databases. Search the Medical Device Recalls database, the MAUDE (Manufacturer and User Facility Device Experience) database, and MedSun (Medical Product Safety Network). Determine why the device was discontinued. Was it a planned commercial transition to a newer generation, or did market withdrawal follow an escalation of adverse event reports, MDR filings, or software anomalies? If postmarket data reveal persistent clinical complications, selecting this predicate will trigger intense scrutiny from CDRH reviewers.

When to use the discontinued predicate anyway — and when to switch

Even when a discontinued device is legally eligible, regulatory strategy requires deciding whether it is the optimal predicate to present to CDRH. In many product categories, a regulatory affairs director must choose between an eight-year-old discontinued comparator with a spotless safety record and an actively sold competitor that has undergone multiple field corrections.

As illustrated in the trade-off matrix, choosing a discontinued predicate with a clean historical record is often vastly superior to selecting a currently marketed comparator that carries unresolved postmarket baggage. Under the 2014 guidance “The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications,” submitters must designate a single primary predicate when multiple comparators are cited. The primary predicate must have the intended use and technological characteristics most similar to the subject device. A discontinued device may serve as your primary predicate without regulatory penalty.

Submitters should also master the formal distinction between secondary predicates and reference devices. While multiple predicates may be cited to combine cleared technological features or anatomical indications (provided they do not create an unapproved 'split predicate' intended use), a reference device is not the predicate used to establish substantial equivalence at Decision Points 1 through 4 of the 510(k) decision tree. The 2014 final guidance limits a reference device to scientific methodology or standard reference values. If a discontinued device is needed only to support a bench method, identify it as a reference device rather than the primary predicate. For the site's selection overview, see secondary predicates versus reference devices in 510(k) filings.

If you must cite a discontinued device that experienced a design-related recall because no other comparator exists within your three-letter product code, construct an uncompromising mitigation narrative. In the bench performance testing discussion and the 510(k) summary, structure your argument as follows:

1. Transparent Problem Statement: Acknowledge the historical recall and cite the exact FDA Recall Number (Z-number) and root cause identified in CDRH records.

2. Design Differentiation: Demonstrate precisely how the subject device's mechanical architecture, electrical insulation, or software algorithms eliminate the root cause of the predicate's failure mode.

3. Targeted Verification Data: Provide empirical bench test data, stress testing, and finite element analyses (FEA) validating that the subject device operates safely across the exact boundary conditions that induced failure in the predicate.

Understanding historical clearance probabilities is critical when planning your regulatory timeline. Review our quantitative analysis on FDA 510(k) success rates and rejection reasons and evaluate whether your submission parameters require exploring the FDA De Novo classification pathway or a PMA versus 510(k) pathway comparison.

Open questions, edge cases, and future regulatory triggers

While the core eligibility of discontinued predicates is clear under current U.S. law, regulatory professionals must remain vigilant regarding unresolved boundary conditions and pending administrative shifts.

Edge Case 1: The cleared-but-never-marketed device

A nuanced scenario arises when a device received a formal 510(k) clearance order (Decision Code SE), but the manufacturer canceled commercial commercialization before a single production unit was distributed into interstate commerce. Does a device that was never actually marketed meet the statutory definition of a “legally marketed device”? Under 21 CFR 807.92(a)(3), a predicate device includes a device “found substantially equivalent through the 510(k) process.” The regulation does not require historical sales volume or patient exposure to validate legal marketing authorization. Legally, the SE order establishes predicate status. However, from an evidentiary standpoint, a predicate with zero real-world commercial history provides no clinical safety baseline. Reviewers may examine the submission with elevated rigor. In this scenario, early engagement via a formal Q-Submission is strongly advised.

Edge Case 2: The orphaned 510(k) Statement with a dissolved manufacturer

As detailed in Step 2, if a candidate predicate relied on a 21 CFR 807.93 Statement and its manufacturer is dissolved, the safety and effectiveness information that FDA says must come from the applicant may be unavailable. A file that cannot identify and compare the predicate's technological characteristics is exposed to an additional-information request, an RTA hold, or an NSE decision. The practical options are another predicate with a public 510(k) Summary, a different legally marketed comparator, or a Pre-Submission to discuss the testing protocol before filing.

Regulatory Triggers: What would change the answer?

Regulatory teams relying on discontinued predicates should monitor several concrete administrative developments:

• Finalization of Draft Predicate Guidance: When FDA finalizes its September 2023 draft guidance (Docket FDA-2023-D-3134), observe whether CDRH incorporates the four best-practice criteria into binding Refusal to Accept (RTA) screening checklists under 21 CFR 807.87, or whether they remain qualitative review recommendations.

• 510(k) Modernization Initiatives: Monitor future CDRH public dockets regarding predicate lifecycle governance. If Congress or FDA revives proposals to sunset predicates based on chronological age or commercial inactivity, statutory amendments to section 513(i) would be required.

• Statutory Amendments to Section 513(i)(2): Any statutory revision altering the threshold for market removal or judicial misbranding determinations would directly impact predicate eligibility.

For software-driven and digital health technologies where predicates evolve rapidly, review our methodology on AI-enabled device predicate mining as well as postmarket modifications under 21 CFR 807.81(a)(3) changes versus PCCP exemptions.